Lipocine shifts focus to CNS; Drug approval triggers capital infusion at Fennec
Lipocine, after a yearslong quest to snag FDA approval for its oral testosterone drug, has decided to shift focus to central …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
